Origine Bio, a Barcelona, Spain-based biopharmaceutical company developing precision-engineered bi-specific cytokine therapies for the treatment of severe autoimmune diseases, raised €800K in innovation research funding.
The round was led by CPP23 innovation health research program, administered by the Spanish government.
The company intend sto use the funds to advance preclinical proof-of-concept for FoldikineTM ORK-1, its drug candidate for autoimmune/inflammatory diseases.
Orikine Bio is a biopharmaceutical company focused on the discovery, research and development of precision-engineered bi-specific cytokine therapies for the treatment of severe autoimmune diseases. Its FoldikineTM technology platform aims to innovate immunotherapy by engineering bi-specific cytokines that go beyond the natural limitations of biology. These optimized proteins, called Foldikines, are designed to precisely control immune responses, offering therapeutic potential for tackling autoimmune, inflammatory and cancerous conditions.
FinSMEs
03/12/2024